Chemogenomic screening of acute myeloid leukemia samples

Acute myeloid leukemia (AML) represents 20% of pediatric leukemia, but accounts for most of disease-related mortality in children, due to chemo-resistance or relapse. Treatment modalities tailored according to specific AML genetic subgroups are critically needed to improve survival and decrease morbidity. To address this need we report here the results of a small molecule screen that was performed using 12,000 compounds using human leukemia models, matched patient diagnostic and relapse samples, and cell lines. As part of this work, expression profiling was performed in order to correlate drug response to gene expression differences between samples.